- Home
- APRE vs SPRB Comparison
APRE vs SPRB Comparison
Compare APRE & SPRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APRE
- SPRB
- Stock Information
- Founded
- APRE 2006
- SPRB 2014
- Country
- APRE United States
- SPRB United States
- Employees
- APRE N/A
- SPRB N/A
- Industry
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- SPRB Medicinal Chemicals and Botanical Products
- Sector
- APRE Health Care
- SPRB Health Care
- Exchange
- APRE Nasdaq
- SPRB Nasdaq
- Market Cap
- APRE 21.3M
- SPRB 22.8M
- IPO Year
- APRE 2019
- SPRB 2020
- Fundamental
- Price
- APRE $2.92
- SPRB $0.49
- Analyst Decision
- APRE Strong Buy
- SPRB Hold
- Analyst Count
- APRE 2
- SPRB 7
- Target Price
- APRE $15.50
- SPRB $2.50
- AVG Volume (30 Days)
- APRE 13.3K
- SPRB 364.9K
- Earning Date
- APRE 11-07-2024
- SPRB 11-11-2024
- Dividend Yield
- APRE N/A
- SPRB N/A
- EPS Growth
- APRE N/A
- SPRB N/A
- EPS
- APRE N/A
- SPRB N/A
- Revenue
- APRE $1,310,839.00
- SPRB $7,101,000.00
- Revenue This Year
- APRE $116.72
- SPRB N/A
- Revenue Next Year
- APRE N/A
- SPRB N/A
- P/E Ratio
- APRE N/A
- SPRB N/A
- Revenue Growth
- APRE 130.31
- SPRB N/A
- 52 Week Low
- APRE $2.15
- SPRB $0.41
- 52 Week High
- APRE $8.85
- SPRB $5.95
- Technical
- Relative Strength Index (RSI)
- APRE 34.50
- SPRB 43.61
- Support Level
- APRE $2.87
- SPRB $0.47
- Resistance Level
- APRE $3.35
- SPRB $0.51
- Average True Range (ATR)
- APRE 0.32
- SPRB 0.03
- MACD
- APRE -0.12
- SPRB -0.01
- Stochastic Oscillator
- APRE 4.50
- SPRB 21.35
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
About SPRB Spruce Biosciences Inc.
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).